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Evidence-based management of adult patients with diffuse glioma: A long and 
winding road 
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We appreciate the interest of our colleagues representing the European low-grade 
glioma network in the updated EANO guidelines (1). Such guidelines often represent 
a multidisciplinary consensus that aims at providing guidance also in areas where 
evidence from conclusive clinical studies is limited or absent. Our colleagues miss a 
specific reference to the value of radiological growth rates. If we did not think that the 
assessment of tumor growth by neuroimaging was important, we would not have 
recommended regular MRI scanning to determine benefit from treatment and need 
for re-intervention. However, no prospective systematic outcome study informs us on 
how to integrate radiological growth rates into clinical decision making, notably 
regarding timepoints of interventions. Furthermore, our colleagues are at odds with 
our assessment of the scientific literature on the role of surgery for adult glioma 
patients. Yet, our assessment of the evidence, which is a result of multi-disciplinary 
consensus involving leading neurosurgeons in Europe, is fully consistent with the 
current Cochrane review (2) which reinforces the need for randomized controlled 
clinical trials in this situation. We agree that the recent longterm follow-up on the 
Norwegian cohort study is suggestive of a benefit of early surgical intervention in 
patients with «low grade» gliomas across the major molecular subtypes (3) and may 
in fact be the best evidence for a role of early surgery in this patient population 
published so far (4). Yet, this cohort study cannot be considered conclusive regarding 
the value of resection, moreover, the article was not available in the public domain 
when we prepared the EANO guideline (1). Finally, it is incorrect to state that 
cognitive function and quality of life assessments are not mentioned: they are in fact 
mentioned as part of the clinical examination, further, this was not the main scope of 
this guideline and the importance of cognitive function and quality of life in the overall 
management strategies for adult glioma patients has recently been addressed in a 
separate EANO guideline (5). 
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